Rhythm Pharmaceuticals Inc expected to post a loss of $2.16 a share - Earnings Preview

Rhythm Pharmaceuticals

03/05/2024 16:05

* Rhythm Pharmaceuticals Inc  RYTM.OQ   RYTM.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 7 for the period ending March 31 2024
    * The Boston Massachusetts-based  company is expected to
report a
134.5% increase in revenue to $26.896 million from $11.47
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Rhythm Pharmaceuticals
Inc is
for a loss of $2.16 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rhythm
Pharmaceuticals Inc is $55.00​, above​ its last closing price
of $40.98. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.69       -0.70      -0.70     Met     -0.3
 Sep. 30 2023  -0.71       -0.74      -0.76     Missed  -2.8
 Jun. 30 2023  -0.79       -0.79      -0.82     Missed  -3.2​
 Mar. 31 2023  -0.73       -0.90      -0.92     Missed  -1.7
 ​​Dec.        -0.77       -0.81      -0.75     Beat    7.3
 31 2022                                                
 Sep. 30 2022  -1.00       -1.00      -0.79     Beat    21.1​
 Jun. 30 2022  -0.93       -0.95      -0.89     Beat    6.1
 Mar. 31 2022  -1.01       -1.01      -1.05     Missed  -3.6
 This summary was machine generated May 3 at 15:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)